TQD3524 Phase 1 trial targets carbapenem-resistant bacterial pneumonia

ClinicalTrials.gov added a new Phase 1 clinical trial registration for TQD3524 (NCT07512596), an investigational drug targeting carbapenem-resistant bacterial pneumonia. The study is categorized under infectious disease drug development with a Phase 1 trial design.

Pharmaceutical sponsors conducting applicable clinical trials must ensure proper registration under FDAAA 801 requirements. Clinical investigators should verify study participation status and protocol compliance. No specific compliance deadlines apply to this study registration; enrollment status should be monitored through ClinicalTrials.gov.